Ditan Acute tReatments: Effectiveness and Tolerability (DART)

Launched by UNIVERSITY OF FLORENCE · Jun 5, 2023

Keywords

ClinConnect Summary

The DART clinical trial is studying a medication called lasmiditan to see how well it works and how well patients tolerate it when treating migraines. This trial includes people who experience different types of migraines—those without aura (which are common), those with aura (which may involve visual disturbances), and chronic migraines that occur frequently. Researchers are looking for participants who have been diagnosed with migraines, have at least three migraine days per month, and have kept a headache diary for at least a month before joining the study.

To be eligible, participants should not have any medical conditions that could interfere with the study or be pregnant or breastfeeding. Those who join can expect to follow specific procedures and report their experiences with the treatment. This research is important because it aims to provide more information on how effective lasmiditan is for managing migraines, potentially helping many people find better relief from their symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III).
• • At least 3 MMDs
• • Good compliance to study procedures
• • Availability of headache diary at least of the preceding months before enrollment
• Exclusion Criteria:
• • Subjects with contraindications for use of ditans;
• • Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
• • medical comorbidities that could interfere with study results;
• • Pregnancy and breastfeeding.